Elutia Q3: $1.1M Sales, $29.1M Cash, NXT-41x FDA Filing Set for Q4
ELUT sits 50% above its 52-week low of $0.5.
Summary
Elutia reported Q3 2026 sales of $1.1 million and a $1.3 million net loss, with $29.1 million of cash, and said it will submit NXT-41x to the FDA in Q4 2026, funded through launch without an equity offering.
Key Events · Earnings and Guidance · ELUT
-
Q3 Sales Grow 20% to $1.1M
Net sales rose to $1.1 million from $0.9 million a year earlier, with adjusted gross margin of 85.5%.
-
NXT-41x FDA Filing Set for Q4
The GLP rabbit study met prespecified endpoints, eradicating 8-log MRSA and 6-log E. coli challenges; Elutia plans to submit NXT-41x to the FDA in Q4 2026, with NXT-41 clearance expected this quarter and NXT-41x clearance in 1H 2027.
-
$26M Raised Without Equity
The Avenue loan, SimpliDerm sale, and Boston Scientific holdback added $26 million in 51 days; cash was $29.1 million at September 30, 2026, before the $8 million holdback received October 1.
-
Losses Continue on R&D Spend
Continuing operations lost $6.5 million versus $1.0 million a year earlier as R&D rose $1.9 million; the $1.3 million net loss included $5.2 million of income from discontinued operations.
Analysis · ELUT · Life Sciences
The path to NXT-41x is the main event in Elutia's Q3 update: the GLP rabbit study cleared its endpoints, the FDA submission is planned for Q4 2026, and management says $26 million raised in 51 days without selling equity funds the company through clearance and the first full year of launch in 2028. Revenue remains tiny at $1.1 million, and the $1.3 million net loss was flattered by $5.2 million of income from discontinued operations while continuing operations lost $6.5 million. Regulatory timing and the Nasdaq delisting issue previously disclosed remain the key risks; a clearance decision on NXT-41 is expected this quarter.
How filings like this one have moved
In the 30 days to Nov 10, 2026, 36.4% of the 3168 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, ELUT was trading at $0.75 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $33.3M. The 52-week trading range was $0.50 to $1.39. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.